Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

A-205804

Cat. No.: HY-100226

A-205804 is an orally bioavailable, potent and selective lead inhibitor of **E-selectin** and **ICAM-1** expression, with an IC_{50} of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Arg-Gly-Asp-Ser

(RGDS peptide; Fibronectin tetrapeptide)

Cat. No.: HY-12290

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits **integrin receptor** function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Arg-Gly-Asp-Ser (TFA)

(RGDS peptide (TFA); Fibronectin tetrapeptide (TFA))

Cat. No.: HY-12290A

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits **integrin receptor** function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

ATN-161

Cat. No.: HY-13535

ATN-161 is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

ATN-161 trifluoroacetate salt

(ATN-161 TFA salt)

Cat. No.: HY-13535A

ATN-161 trifluoroacetate salt is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



Purity: >95.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

BI-1950

Cat. No.: HY-124040

BI-1950 is a highly potent **lymphocyte function associated antigen-1 (LFA-1)** inhibitor. LFA-1 is an essential component in normal immune system function and a target for drug discovery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIO5192

Cat. No.: HY-107589

BIO5192 is a selective and potent integrin **α4β1** (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC_{50}=1.8 μM) over a range of other integrins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-688521

Cat. No.: HY-10596

BMS-688521 is a highly potent, orally active inhibitor of the **LFA-1/ICAM** interaction, with an IC_{50} of 2.5 nM in the adhesion assay and an IC_{50} of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

c(phg-isoDGR-(NMe)k)

Cat. No.: HY-111413

c(phg-isoDGR-(NMe)k) is a selective and potent **α5β1-integrin** ligand with an IC_{50} of 2.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

c(phg-isoDGR-(NMe)k) TFA

Cat. No.: HY-111413A

c(phg-isoDGR-(NMe)k) TFA is a selective and potent **α5β1-integrin** ligand with an IC_{50} of 2.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Carotegrast

Cat. No.: HY-14857

Carotegrast is an orally available **α4 integrin receptor** inhibitor with anti-inflammatories activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cilengitide

(EMD 121974)

Cat. No.: HY-16141

Cilengitide, a cyclic RGD-containing peptide, is a potent and selective **integrin** inhibitor for $\alpha_v\beta_3$ and $\alpha_v\beta_5$ receptor, with **IC_{50}**s of 4 and 79 nM, respectively.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cucurbitacin B

Cat. No.: HY-N0416

Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

CWHM-12

Cat. No.: HY-18644

CWHM-12 is a potent inhibitor of **αV integrins** with **IC_{50}**s of 0.2, 0.8, 1.5, and 1.8 nM for **αvβ8**, **αvβ3**, **αvβ6**, and **αvβ1**.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cyclo(-RGDfK)

Cat. No.: HY-P0023

Cyclo(-RGDfK) is a potent and selective inhibitor of the $\alpha_v\beta_3$ integrin, with an **IC_{50}** of 0.94 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cyclo(-RGDfK) TFA

Cat. No.: HY-P0023A

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the $\alpha_v\beta_3$ integrin, with an **IC_{50}** of 0.94 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

Cat. No.: HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of **integrin αvβ3**, with antitumor activity.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclo(RADfK)

Cat. No.: HY-P0031

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg

Cyclo(RGDyK)

Cat. No.: HY-100563A

Cyclo(RGDyK) is a potent and selective **$\alpha_v\beta_3$ integrin** inhibitor with an **IC_{50}** of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclo(RGDyK) trifluoroacetate

Cat. No.: HY-100563

Cyclo(RGDyK) trifluoroacetate is a potent and selective **$\alpha_v\beta_3$ integrin** inhibitor with an **IC_{50}** of 20 nM.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E7820

(ER68203-00)

Cat. No.: HY-14571

E7820 is an angiogenesis inhibitor by suppressing **integrin a2**, a cell adhesion molecule expressed on endothelial cells.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Eptifibatide

Cat. No.: HY-B0686

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



Purity: 96.49%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Eptifibatide acetate

Cat. No.: HY-B0686A

Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Firategrast

(SB 683699)

Cat. No.: HY-14951

Firategrast is an orally bioavailable **α4β1/α4β7 integrin** antagonist.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fradafiban

(BIBU-52)

Cat. No.: HY-101720

Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a K_d value of 148 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

GLPG0187

Cat. No.: HY-100506

GLPG0187 is a broad spectrum **integrin** receptor antagonist with antitumor activity; inhibits $\alpha_v\beta_1$-integrin with an IC_{50} of 1.3 nM.



Purity: 98.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Gly-Arg-Gly-Asp-Ser

Cat. No.: HY-P0295

Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC_{50} of 5 and 6.5 μM.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg

Gly-Arg-Gly-Asp-Ser (TFA)

Cat. No.: HY-P0295A

Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to **integrin receptors** αvβ3 and αvβ5 with estimated IC_{50} of 5 and 6.5 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

GRGDSP

Cat. No.: HY-P0290

GRGDSP, a synthetic linear RGD peptide, is an **integrin** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GRGDSP TFA

Cat. No.: HY-P0290A

GRGDSP (TFA) is an **integrin** inhibitor.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

ICAM-1-IN-1

Cat. No.: HY-U00003

ICAM-1-IN-1 is a potent and selective inhibitor of **E-selectin** and **ICAM-1** with IC_{50} values of 7 and 5 nM, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

ILK-IN-2

(OSU-T315 analog)

Cat. No.: HY-18676B

ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

ILK-IN-3

Cat. No.: HY-115677

ILK-IN-3 is an **integrin linked kinase** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Integrin Antagonists 27

Cat. No.: HY-18668

Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Integrin-IN-2

Cat. No.: HY-130119

Integrin-IN-2 (compound 39) is an orally bioavailable pan **αv integrin** inhibitor. Integrin-IN-2 can increases the **αvβ6**, **αvβ3**, **αvβ5** and **αvβ8** binding affinities with pIC_{50} values of 7.8, 8.4, 8.4 and 7.4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

iRGD peptide

(c(CRGDKGPDC))

Cat. No.: HY-P0122

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to **av integrins**, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

Purity: 98.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Irigenin

Cat. No.: HY-N2587

Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking **α9β1** and **α4β1** integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

LDV

Cat. No.: HY-P2267

LDV, a non-fluorescent derivative of LDV FITC, is a **α4β1 integrin (VLA-4)** ligand (K_d ~ 12 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leukadherin-1

Cat. No.: HY-15701

Leukadherin-1 is a specific agonist of complement receptor 3 (**CR3**) and the leukocyte surface **αMβ2 integrin CD11b/CD18**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Lifitegrast

(SAR 1118; SHP-606)

Cat. No.: HY-19344

Lifitegrast (SAR 1118) is an integrin lymphocyte function-associated antigen-1 (**LFA-1**) antagonist; inhibits Jurkat T cell attachment to **ICAM-1** with an IC_{50} of 2.98 nM.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

LXW7

Cat. No.: HY-P0178

LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), has a high binding affinity to **αvβ3 integrin** with an IC_{50} of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LXW7 TFA

Cat. No.: HY-P0178A

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), has a high binding affinity to **αvβ3 integrin** with an IC_{50} of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MK-0429

(L-000845704)

Cat. No.: HY-15102

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide **αvβ3 integrin** antagonist with an IC_{50} of 80 nM.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Natalizumab

Cat. No.: HY-108831

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-**integrin** and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 25 mg

OSU-T315

Cat. No.: HY-18676

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase **(ILK)** inhibitor with an IC_{50} of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Pyrintegrin

Cat. No.: HY-13306

Pyrintegrin is an **β1-integrin** agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated **integrin** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

RGD

Cat. No.: HY-P0278

RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to **integrins**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

RGD peptide (GRGDNP)

Cat. No.: HY-P1740

RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RGD peptide (GRGDNP) (TFA)

Cat. No.: HY-P1740A

RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

RGD Trifluoroacetate

Cat. No.: HY-P0278A

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to **integrins**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RWJ 50271

Cat. No.: HY-110086

RWJ 50271 is an selective inhibitor of **lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1)** interaction with an IC_{50} of 5.0 μM (HL60 cells).



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SB-267268

Cat. No.: HY-19306

SB-267268 is a selective and nonpeptidic **alpha(v)beta3 (αvβ3)** and **alpha(v)beta5 (αvβ5)** integrins antagonist, with K_is of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR121566A

Cat. No.: HY-U00235

SR121566A is a novel non-peptide **Glycoprotein IIb/IIIa** (**GP IIb-IIIa**) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC_{50}s of 46±7.5, 56±6 and 42±3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCS 2314

Cat. No.: HY-12308

TCS 2314 (compound 3) is orally active and selective **very late antigen-4 (VLA-4, α4β1, CD49d/CD29)** antagonist with an IC_{50} of 4.4 nM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg

Tirofiban

(L700462; MK383)

Cat. No.: HY-17369B

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tirofiban hydrochloride monohydrate

Cat. No.: HY-17369

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist IC50 value: Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TR-14035

Cat. No.: HY-15770

TR-14035 is a a dual alpha4beta7(IC50=7 nM)/alpha4beta1 (IC50=87 nM) integrin antagonist .



Purity: 95.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Valategrast

(R-411 free base)

Cat. No.: HY-14190

Valategrast (R-411 free base) is a potent and orally active **integrin α4β1 (VLA-4)** and **α4β7** dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vedolizumab

(Anti-Human lymphocyte α4β7 integrin, Humanized Antibody) Cat. No.: HY-P9911

Vedolizumab is a humanized monoclonal antibody that targets the α4β7 **integrin** for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab

Purity: 99.64%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Zaurategrast

(CT7758)

Cat. No.: HY-70073

Zaurategrast (CT7758) is a potent and oral-effective **α_4-integrin** inhibitor.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Zauategrast ethyl ester

(CDP323; UCB1184197) **Cat. No.:** HY-75385

Zauategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Zauategrast ethyl ester sulfate

(CDP323 sulfate; UCB1184197 sulfate) **Cat. No.:** HY-75385A

Zauategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α2β1 Integrin Ligand Peptide

Cat. No.: HY-P1868

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

α2β1 Integrin Ligand Peptide TFA

Cat. No.: HY-P1868A

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

αvβ1 integrin-IN-1

Cat. No.: HY-100445

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an IC_{50} of 0.63 nM. Antifibrotic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

αvβ1 integrin-IN-1 TFA

Cat. No.: HY-100445A

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an IC_{50} of 0.63 nM. Antifibrotic effects.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg